Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Nebraska Oncology Society
E

2020 ASCO Update on RET-Altered Thyroid Cancer: What Is the Efficacy of New RET Inhibitors? Should We Use Them 1L or 2L?

By Nebraska Oncology Society FEATURING Eric Sherman
By Nebraska Oncology Society FEATURING Eric Sherman
0 views
January 5, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
Head and Neck
08:09
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "AIM-HN Study Evaluating Tipifarnib in mHRA…

Feat. A. Ho
18:07
Nebraska Oncology Society

NOS ASCO® 2023 Review: Nasopharynx Cancer

Feat. E. Sherman
22:27
Nebraska Oncology Society

NOS ASCO® 2023 Review: Head & Neck Cancer De-Escalation

Feat. E. Sherman
47:18
Nebraska Oncology Society

ASCO 2022 Review of Head & Neck Cancer Updates

Feat. E. Sherman
09:41
Nebraska Oncology Society

ASCO 2020 Review of Transoral Robotic Surgery for OPC : Is 2-yr PFS …

Feat. E. Sherman
09:24
Nebraska Oncology Society

2020 ASCO LA-HNSCC Trials Review: What Is the Efficacy of Weekly CDD…

Feat. E. Sherman
11:38
Nebraska Oncology Society

ASCO 2020 Update on DO-IMRT & HNC Metastatic: Does Change in IMR…

Feat. E. Sherman
04:56
Nebraska Oncology Society

2020 ASCO Update on Metastatic/Recurrent HNSCC: What Is the Efficacy…

Feat. E. Sherman
08:09
Nebraska Oncology Society

2020 ASCO Update on RET-Altered Thyroid Cancer: What Is the Efficacy…

Feat. E. Sherman